Italy Pulmonary Arterial Hypertension Market Outlook

italy pulmonary arterial hypertension (pah) market outlook provides an intricate overview of the view of pulmonary arterial hypertension procedures and treatments in the country. the document assesses the technology infrastructure, penetration rates, regulatory environment, market participants, and pricing structure which govern the market’s competitive landscape. the study is furthermore framed to assess the comprehensive landscape of pah treatments and therapies in the italian market, derived from an analysis of data points sourced from comprehensive industry surveys and interviews with medical professionals and market professionals. the scope of the report furthermore covers the pharmaceutical landscape in the country, staying abreast with developments as well as recent drugs and products that are in development or under assessment for their market entry. the italian pah market continues to see the emergence of therapies from both new and existing players. to keep up pace with changes to the health care industry landscape, many pah providers have proactively reorganized and adapted how they interact with health care professionals, as well as in the way they market their products or services. the increased pressure from value-based healthcare has also changed the competitive landscape of the italian pah market. regulatory strong points in the italian pah market include the presence of the agency for drug prevention and control (aifa) in the pharmaceutical market, which provides a degree of control on the marketing of drugs by stimulation guidelines and restrictions. data from clinicaltrials.gov indicates that the number of clinical research studies in italy related to pulmonary arterial hypertension treatments have remained relatively stagnant since 2015, before picking up from 2017. the italian pah market serums to be increasingly competitive due to the presence of drug manufacturers and associations, companies providing services related to pulmonary arterial hypertension who are counting on localised promotions into the italian market, not to mention online pharmacies. high-level customer service and integrative patient care are important tangible drivers of demand for pulmonary hypertension services, as reflected by the investment and pressure placed on the sector. overall, the market outlook for the pulmonary arterial hypertension treatments in the italian market paints a positive outlook for the sector but one that expresses therapeutic needs. the thursday market remains strong, marked by diverse competition and numerous opportunities for new and existing pah market players. references: llort a, et al. "pulmonary arterial hypertension in europe: a multicenter observational study." chest, vol. 155, no. 2, 2019, pp. 366-373. accessed 15 jan. 2020 clinicaltrials.gov [internet]. bethesda (md): national library of medicine (us); 2000 - [cited 2020 jan 15]. available from: https://clinicaltrials.gov/